SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Nasus Pharma Ltd. NSRX NYSE

NYSE • Healthcare • Biotechnology • IL • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Nasus Pharma Ltd. (NSRX) is a Biotechnology company in the Healthcare sector, currently trading at $2.21. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is NSRX = $22 (+895.5% upside).

Valuation: NSRX trades at a trailing Price-to-Earnings (P/E) of -13.6 (S&P 500 average ~25).

Net income is $2M (loss), growing at -3.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Analyst outlook: 1 / 1 analysts rate NSRX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$22.00

▲ 895.48% Upside

Average Price Target

The 12-month price target for Nasus Pharma Ltd. is $22.00.

NSRX SharesGrow Score Overview

55/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NSRX

NSRX trades at a trailing Price-to-Earnings (P/E) of -13.6 (S&P 500 average ~25). Forward PEG -0.14 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $22, implying +895.5% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

NSRX: +0%/yr revenue is, -3.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet NSRX: Debt-to-Equity (D/E) ratio N/A, Current ratio is N/A. Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

NSRX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate NSRX as buy (100%). Analyst consensus target is $22 (+895.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range1.98-9.99

Volume38.59K

Avg Volume (30D)169.26K

Market Cap$19.03M

Beta (1Y)-1.70

Share Statistics

EPS (TTM)-0.17

Shares Outstanding$9.06M

IPO Date2025-08-13

Employees2

CEODan Teleman

Financial Highlights & Ratios

EBITDA$-1.52M

Net Income$-1.53M

Operating Income$-1.08M

Price / Earnings (P/E)-13

Analyst Forecast

1Y Price Target$22.00

Target High$22.00

Target Low$22.00

Upside+895.5%

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Price Target Summary

Company Info

CountryIL

ExchangeNYSE

CurrencyUSD

ISINIL0012181553

Price Chart

NSRX

Nasus Pharma Ltd. ↗ · NYSE

Healthcare • Biotechnology

1.98 52WK RANGE 9.99

People Also View

Gain Therapeutics, Inc.

Fortress Biotech, Inc.

Adicet Bio, Inc.

TScan Therapeutics, Inc.

Acrivon Therapeutics, Inc. Common Stock

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message